{"id":36428,"date":"2026-11-09T17:27:00","date_gmt":"2026-11-09T11:57:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=36428"},"modified":"2026-11-09T12:01:07","modified_gmt":"2026-11-09T06:31:07","slug":"emerging-intratumoral-cancer-therapies","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies","title":{"rendered":"Top 5 Late-Stage Intratumoral Cancer Therapies Redefining the Oncology Pipeline"},"content":{"rendered":"\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>Intratumoral cancer therapies represent an emerging immunotherapy approach that directly targets the tumor microenvironment, enhances localized drug delivery, minimizes systemic toxicity, and potentially converts immunologically cold tumors into hot tumors responsive to immune-based treatment.<\/em><\/li>\n\n\n\n<li><em>Despite a rapidly expanding clinical pipeline, commercial penetration remains limited, with only three therapies reported as approved: Amgen\u2019s IMLYGIC (2015, US\/EU), Daiichi Sankyo\u2019s DELYTACT (2021, Japan), and Oncolys BioPharma\u2019s telomelysin (2026, Japan), Replimune\u2019s TUDRIQEV (2026, US), and highlighting substantial regulatory and commercialization challenges.<\/em><\/li>\n\n\n\n<li><em>Promising late-stage candidates in the pipeline include JNJ-1900\/NBTXR3 (NANOBIOTIX\/Johnson &amp; Johnson), CAN-2409 (Candel Therapeutics), Multikine (CEL-SCI), INT230-6 (Intensity Therapeutics), and NIDLEGY (Daromun; Philogen S.p.A.).<\/em><\/li>\n<\/ul>\n\n\n\n<p>Intratumoral therapies are transforming cancer immunotherapy by directly modifying the tumor microenvironment (TME), enabling high drug concentrations at the tumor site while minimizing systemic toxicity and potentially converting immunologically \u201ccold\u201d tumors into \u201chot\u201d tumors that are more responsive to immune-mediated treatment.&nbsp;<\/p>\n\n\n\n<p>Despite substantial clinical development efforts, regulatory <a href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-intratumoral-cancer-therapy\">approvals for intratumoral therapies<\/a> remain relatively scarce. To date, only a handful of agents have reached commercialization, including <strong>talimogene laherparepvec<\/strong> (IMLYGIC, Amgen), approved in the US and EU in 2015 for unresectable melanoma; <strong>teserpaturev\/G47\u2206<\/strong> (DELYTACT, Daiichi Sankyo), approved in Japan in 2021 for malignant glioma; and <strong>telomelysin <\/strong>(OBP-301; Oncolys BioPharma), approved in Japan in 2026 for locally advanced esophageal cancer.<\/p>\n\n\n\n<p>More recently, <strong>vusolimogene oderparepvec-wtpg<\/strong> (TUDRIQEV, Replimune) received FDA accelerated approval on August 6, 2026, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that has progressed following anti-PD-1 therapy.<\/p>\n\n\n\n<p>Although talimogene laherparepvec (IMLYGIC) was the <a href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-virus-cancer-therapy\">first approved intratumoral oncolytic viral therapy<\/a>, its commercial performance has remained modest. Key challenges include the lack of a demonstrated overall survival benefit, stringent ultra-cold storage requirements of \u221270\u00b0C, and increasing competition from systemic immune checkpoint inhibitors with broader therapeutic applicability.<\/p>\n\n\n\n<p>Commercial uptake is anticipated to be strongest in tumor types that are readily accessible for intratumoral administration and where resistance to immune checkpoint inhibitors represents a significant unmet clinical need. These characteristics position melanoma, head and neck squamous cell carcinoma (HNSCC), superficial skin malignancies, and selected accessible metastatic lesions as promising opportunities for intratumoral treatment adoption.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market\">intratumoral therapy pipeline<\/a> is increasingly diversified, encompassing a broad spectrum of innovative and late-stage candidates, including <strong>JNJ-1900<\/strong> (HENSIFY, NBTXR3; NANOBIOTIX\/Johnson &amp; Johnson), <strong>INT230-6<\/strong> (Intensity Therapeutics), <strong>NIDLEGY <\/strong>(Daromun; Philogen S.p.A.), <strong>Aglatimagene besadenovec<\/strong> <strong>(CAN-2409) + valacyclovir<\/strong>&nbsp; (Candel Therapeutics), and <strong>MULTIKINE<\/strong> (CEL-SCI).<\/p>\n\n\n\n<p><em>Sadaf Javed, Functional Head of Forecasting &amp; Analytics at DelveInsight, said that the uptake of emerging ITCT therapies is expected to vary based on clinical efficacy, durability of response, safety, tumor type, administration route, combination potential, physician familiarity, and reimbursement. CY-101, JNJ-1900 (HENSIFY\/NBTXR3), and BO-112 may achieve relatively faster or moderate adoption as clinical evidence matures, particularly where combination with checkpoint inhibitors demonstrates meaningful benefit. SP-002 (ASN-002), INT230-6, Hiltonol (Poly ICLC), Voyager V1, and VG161 are expected to see gradual uptake as efficacy, durability, safety, and long-term outcomes become established.<\/em><\/p>\n\n\n\n<p><em>Below is a comprehensive review of five late-stage pipeline candidates expected to enter the intra-tumoral cancer therapies space in the coming years.<\/em><\/p>\n\n\n\n<p><strong>NANOBIOTIX\/Johnson &amp; Johnson\u2019s JNJ-1900 (HENSIFY, NBTXR3)<\/strong><\/p>\n\n\n\n<p><em>Radioenhancer<\/em><\/p>\n\n\n\n<p><strong>NBTXR3 <\/strong>is engineered to amplify radiotherapy\u2019s tumor-killing potential by enhancing radiation absorption and energy deposition within cancer cells while sparing surrounding healthy tissues. Beyond localized tumor destruction, the technology aims to trigger an immune response capable of targeting metastatic disease, potentially extending the benefits of radiation beyond the primary tumor. Building on this differentiated mechanism, NANOBIOTIX plans to explore additional indications in 2026, supported by a growing clinical data package, including updated Phase I results in NSCLC, new data from the expanded PDAC cohort, final results across multiple tumor types resistant to PD-1 inhibitors, updated esophageal cancer data, and determination of the recommended Phase II dose (RP2D) in the protein cohort.<\/p>\n\n\n\n<p>As of May 2026, JNJ-1900 is advancing through a Phase III trial in <a href=\"https:\/\/www.delveinsight.com\/report-store\/head-and-neck-squamous-cell-carcinoma-market\">patients with locally advanced head and neck squamous cell carcinoma (HNSCC)<\/a>, marking a pivotal step toward potential commercialization. NANOBIOTIX expects to complete patient enrollment, conduct the final analysis, and pursue global registration in H1 2027. Further strengthening its clinical pipeline, results from the second part of the randomized Phase II study evaluating NBTXR3 in Stage III NSCLC are <strong>anticipated in early 2027<\/strong>, providing additional evidence to support the technology\u2019s broader therapeutic potential.<\/p>\n\n\n\n<p><strong>Intensity Therapeutics\u2019 INT230-6<\/strong><\/p>\n\n\n\n<p><em>Small molecule<\/em><\/p>\n\n\n\n<p><strong>INT230-6<\/strong> is an innovative intratumoral cancer therapy combining cisplatin and vinblastine with a proprietary amphiphilic cell-penetration enhancer, 8-(2-hydroxybenzoyl amino octanoate) (SHAO). Designed to optimize localized drug delivery, SHAO enhances the dispersion of both chemotherapeutic agents throughout injected tumors and facilitates their penetration into cancer cells, while nonclinical safety studies demonstrated no detectable drug penetration into healthy tissues. INT230-6 is currently advancing through multiple Phase II clinical cohorts across the US and Canada, evaluating its potential in various metastatic cancers. The therapy received <strong>FDA Fast Track designation <\/strong>for relapsed\/metastatic triple-negative breast cancer (TNBC) in 2019 and <strong>Orphan Drug Designation (ODD) <\/strong>for soft tissue sarcoma (STS) in 2023, highlighting its potential in addressing high unmet medical needs.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"705\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Comparison-of-Emerging-Intratumoral-Cancer-Therapies-Under-Development-1024x705.webp\" alt=\"Comparison of Emerging Intratumoral Cancer Therapies Under Development\" class=\"wp-image-35939\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Comparison-of-Emerging-Intratumoral-Cancer-Therapies-Under-Development-1024x705.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Comparison-of-Emerging-Intratumoral-Cancer-Therapies-Under-Development-300x207.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Comparison-of-Emerging-Intratumoral-Cancer-Therapies-Under-Development-150x103.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Comparison-of-Emerging-Intratumoral-Cancer-Therapies-Under-Development-768x529.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Comparison-of-Emerging-Intratumoral-Cancer-Therapies-Under-Development-1536x1057.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Comparison-of-Emerging-Intratumoral-Cancer-Therapies-Under-Development.webp 1569w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>Philogen S.p.A.\u2019s NIDLEGY (Daromun)<\/strong><\/p>\n\n\n\n<p><em>Recombinant fusion protein<\/em><\/p>\n\n\n\n<p><strong>NIDLEGY <\/strong>is an innovative combination of two immunocytokines, L19IL2 and L19TNF, being developed as an intralesional therapy for advanced locoregional melanoma and non-melanoma skin cancers. The combination has demonstrated remarkable anti-tumor activity in preclinical melanoma models, achieving complete tumor eradication in all treated animals.<\/p>\n\n\n\n<p>Clinical findings have further reinforced NIDLEGY\u2019s therapeutic potential. In a Phase II study involving patients with Stage III\/IVM1a melanoma, intralesional administration induced complete responses not only in injected lesions but also in the majority of non-injected tumors, highlighting its ability to trigger a systemic anti-tumor immune response.<\/p>\n\n\n\n<p>Building on these encouraging results, a <strong>Phase III trial<\/strong> in patients with locally advanced melanoma demonstrated that intralesional NIDLEGY followed by surgery delivered statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared with surgery alone. These findings were presented at <strong>ASCO 2024<\/strong>. Philogen has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), which has also approved a combination-pack request for NIDLEGY. A second <strong>Phase III study<\/strong> in locally advanced melanoma is currently underway across the United States and Europe.<\/p>\n\n\n\n<p>Expanding its clinical potential, Philogen has initiated a U.S.-based Phase II trial evaluating intralesional NIDLEGY in combination with systemic <a href=\"https:\/\/www.delveinsight.com\/blog\/pd-1-inhibitors-by-companies\">anti-PD-1 therapy<\/a> in patients whose disease has progressed following immune checkpoint inhibitor treatment. Encouraged by its promising melanoma performance, Philogen is also advancing two Phase II clinical programs investigating NIDLEGY in injectable, locally advanced basal cell carcinoma and other non-melanoma skin cancers, broadening its potential application across dermatological oncology.<\/p>\n\n\n\n<p>The development program is partnered with <strong>SUN Pharmaceuticals<\/strong> for the treatment of skin cancers across Europe, Australia, and New Zealand.<\/p>\n\n\n\n<p><strong>Candel Therapeutics\u2019 Aglatimagene besadenovec (CAN-2409) + valacyclovir&nbsp;<\/strong><\/p>\n\n\n\n<p><em>Oncolytic virus<\/em><\/p>\n\n\n\n<p><strong>Aglatimagene besadenovec<\/strong> is an investigational, off-the-shelf, replication-defective adenoviral gene therapy designed to transform tumors into personalized immune targets. By delivering the herpes simplex virus thymidine kinase (HSV-tk) gene directly into tumor cells, the therapy enables local conversion of orally administered valacyclovir into a cytotoxic metabolite, selectively killing cancer cells in the tumor microenvironment. Beyond direct tumor killing, this mechanism is designed to activate a potent, individualized CD8+ T-cell-mediated immune response against both injected tumors and distant, uninjected metastases. Functioning as an <strong>in situ cancer vaccine<\/strong>, aglatimagene besadenovec leverages a broad repertoire of tumor antigens to generate systemic anti-tumor activity, positioning it as a potentially versatile therapeutic platform across multiple solid tumor indications.<\/p>\n\n\n\n<p>The therapy has secured several key FDA designations, including <strong>Fast Track Designation (FTD) <\/strong>for <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\">non-small cell lung cancer (NSCLC)<\/a> and pancreatic ductal adenocarcinoma (PDAC) in 2023, <strong>Orphan Drug Designation (ODD) <\/strong>for pancreatic cancer in 2024, and <strong>Regenerative Medicine Advanced Therapy (RMAT) Designation <\/strong>for localized intermediate- to high-risk prostate cancer in 2025. In March 2025, Candel Therapeutics further strengthened its commercialization strategy through a collaboration with <strong>IDEA Pharma<\/strong>.<\/p>\n\n\n\n<p><strong>CEL-SCI\u2019s MULTIKINE<\/strong><\/p>\n\n\n\n<p><em>Small molecule<\/em><\/p>\n\n\n\n<p><strong>Multikine <\/strong>is an investigational immunotherapy being developed to harness the body&#8217;s natural immune defenses against cancer. The therapy is being evaluated for multiple indications, including squamous cell carcinoma of the head and neck (SCCHN), cervical dysplasia, and peri-anal warts in patients co-infected with HIV and HPV. Its lead development program focuses on <strong>neoadjuvant treatment of SCCHN<\/strong>, with administration before surgery, radiation, or chemotherapy, at a stage when the immune system may be more capable of mounting a robust anti-tumor response.<\/p>\n\n\n\n<p>Multikine represents a potentially differentiated approach to cancer immunotherapy, combining <strong>active and passive immune mechanisms<\/strong> within a single treatment. It is a defined, off-the-shelf formulation of naturally occurring immune-signaling molecules, including interleukins, interferons, chemokines, and colony-stimulating factors. These cytokines work collectively to stimulate and coordinate the body&#8217;s immune response, without requiring externally supplied tumor antigens.<\/p>\n\n\n\n<p>Designed for scalable manufacturing and potentially cost-efficient production, Multikine aims to establish a new paradigm in immunotherapy by <strong>activating the immune system early, before conventional cancer treatments begin<\/strong>. If successfully developed and approved, it could offer a novel combination-immunotherapy strategy that leverages the body&#8217;s existing immune capabilities to target cancer.<\/p>\n\n\n\n<p>Apart from these late-stage <a href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market\">intra-tumoral cancer therapies<\/a>, several other investigational treatments including <strong>RP2<\/strong> (Replimune), <strong>Ruxotemitide <\/strong>(LTX-315\/VP-315; Lytix Biopharma\/Verrica Pharmaceuticals), <strong>LSAM-PTX<\/strong> (NanoPac; NanOlogy), <strong>LOAd703 <\/strong>(Delolimogene mupadenorepvec; Lokon Pharma), <strong>VG161<\/strong> (Virogin Biotech), <strong>BO-112<\/strong> (Highlight Therapeutics), <strong>Tigilanol Tiglate<\/strong> (QB46C-H07; QBiotics), <strong>SP-002<\/strong> (ASN-002; Stamford Pharmaceuticals\/Ascend Biopharmaceuticals), <strong>AdAPT-001 <\/strong>(EpicentRx), <strong>Bizaxofusp <\/strong>(MDNA55; Medicenna Therapeutics), <strong>SYNC-T SV-102<\/strong> (Syncromune), <strong>Hiltonol <\/strong>(Poly ICLC; Oncovir), <strong>CY-101<\/strong> (CyPep-1; Cytovation ASA), <strong>KB707 <\/strong>(Krystal Biotech), <strong>MVR-T3011<\/strong> formerly called T-3011 (ImmVira Pharma), <strong>T3P-Y058-739 + Pembrolizumab<\/strong> (T3 Pharmaceuticals AG), <strong>STX-001<\/strong> (Strand Therapeutics), <strong>TILT-123<\/strong> (igrelimogene Iitadenorepvec; TILT Biotherapeutics), <strong>MEM-288<\/strong> (Memgen), and others are currently in the mid and early stage of development.&nbsp;<\/p>\n\n\n\n<p>These programs leverage diverse therapeutic modalities, including oncolytic viruses, immunotherapies, gene therapies, nanoparticle-based approaches, and radio-enhancer platforms, reflecting the growing technological breadth and therapeutic potential of this field.<\/p>\n\n\n\n<p>In conclusion, the intratumoral cancer therapy landscape is poised for a significant transformation as emerging candidates progress toward regulatory approval and commercialization. The anticipated entry of therapies such as JNJ-1900, NIDLEGY, INT230-6, CAN-2409, and MULTIKINE could expand treatment options beyond conventional <a href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-cancer-therapy-market\">oncolytic viral approaches<\/a>, introducing differentiated mechanisms of action, broader tumor applicability, and new opportunities for combination strategies with immune checkpoint inhibitors, radiotherapy, and other systemic treatments. Successful commercialization of these agents could reshape treatment paradigms by improving local tumor control, stimulating systemic anti-tumor immunity, and addressing resistance in immunologically cold tumors and checkpoint inhibitor-refractory malignancies.&nbsp;<\/p>\n\n\n\n<p>Furthermore, increasing clinical validation and regulatory success are likely to strengthen physician confidence, accelerate market adoption, and attract further investment into the intratumoral therapy pipeline. While challenges related to clinical efficacy, durability of response, administration complexity, patient selection, and reimbursement will continue to influence uptake, the approval of these next-generation therapies could establish intratumoral immunotherapy as an increasingly important component of multimodal cancer treatment, ultimately driving a more diversified, personalized, and immune-driven oncology treatment landscape.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Intratumoral-Cancer-Therapies-Market-Outlook-1024x194.webp\" alt=\"Intratumoral Cancer Therapies Market Outlook\" class=\"wp-image-35936\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Intratumoral-Cancer-Therapies-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Intratumoral-Cancer-Therapies-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Intratumoral-Cancer-Therapies-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Intratumoral-Cancer-Therapies-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Intratumoral-Cancer-Therapies-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Intratumoral-Cancer-Therapies-Market-Outlook.webp 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary Intratumoral therapies are transforming cancer immunotherapy by directly modifying the tumor microenvironment (TME), enabling high drug concentrations at the tumor site while minimizing systemic toxicity and potentially converting immunologically \u201ccold\u201d tumors into \u201chot\u201d tumors that are more responsive to immune-mediated treatment.&nbsp; Despite substantial clinical development efforts, regulatory approvals for intratumoral therapies remain relatively scarce. [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":36430,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22215,22214,23179,18826,18827,22186],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-36428","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-delytact","tag-imlygic","tag-intratumoral-cancer-therapies","tag-intratumoral-cancer-therapy","tag-intratumoral-cancer-therapy-market","tag-oncolytic-virus-cancer-therapy","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>5 Emerging Intratumoral Cancer Therapies on the Oncology Radar<\/title>\n<meta name=\"description\" content=\"Promising intratumoral cancer therapies in pipeline include JNJ-1900\/NBTXR3, CAN-2409, Multikine, INT230-6, and others\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"5 Emerging Intratumoral Cancer Therapies on the Oncology Radar\" \/>\n<meta property=\"og:description\" content=\"Promising intratumoral cancer therapies in pipeline include JNJ-1900\/NBTXR3, CAN-2409, Multikine, INT230-6, and others\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-09T11:57:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/emerging-intratumoral-cancer-therapies.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"5 Emerging Intratumoral Cancer Therapies on the Oncology Radar","description":"Promising intratumoral cancer therapies in pipeline include JNJ-1900\/NBTXR3, CAN-2409, Multikine, INT230-6, and others","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies","og_locale":"en_US","og_type":"article","og_title":"5 Emerging Intratumoral Cancer Therapies on the Oncology Radar","og_description":"Promising intratumoral cancer therapies in pipeline include JNJ-1900\/NBTXR3, CAN-2409, Multikine, INT230-6, and others","og_url":"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-11-09T11:57:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/emerging-intratumoral-cancer-therapies.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"Top 5 Late-Stage Intratumoral Cancer Therapies Redefining the Oncology Pipeline","datePublished":"2026-11-09T11:57:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies"},"wordCount":1800,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/emerging-intratumoral-cancer-therapies.webp","keywords":["DELYTACT","IMLYGIC","Intratumoral Cancer Therapies","Intratumoral Cancer Therapy","Intratumoral Cancer Therapy Market","Oncolytic Virus Cancer Therapy"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies","url":"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies","name":"5 Emerging Intratumoral Cancer Therapies on the Oncology Radar","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/emerging-intratumoral-cancer-therapies.webp","datePublished":"2026-11-09T11:57:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Promising intratumoral cancer therapies in pipeline include JNJ-1900\/NBTXR3, CAN-2409, Multikine, INT230-6, and others","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-intratumoral-cancer-therapies#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/emerging-intratumoral-cancer-therapies.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/emerging-intratumoral-cancer-therapies.webp","width":466,"height":284,"caption":"emerging-intratumoral-cancer-therapies"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/emerging-intratumoral-cancer-therapies-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DELYTACT<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IMLYGIC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Intratumoral Cancer Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Intratumoral Cancer Therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Intratumoral Cancer Therapy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncolytic Virus Cancer Therapy<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DELYTACT<\/span>","<span class=\"advgb-post-tax-term\">IMLYGIC<\/span>","<span class=\"advgb-post-tax-term\">Intratumoral Cancer Therapies<\/span>","<span class=\"advgb-post-tax-term\">Intratumoral Cancer Therapy<\/span>","<span class=\"advgb-post-tax-term\">Intratumoral Cancer Therapy Market<\/span>","<span class=\"advgb-post-tax-term\">Oncolytic Virus Cancer Therapy<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 day ago","modified":"Updated 2 days ago"},"absolute_dates":{"created":"Posted on Nov 9, 2026","modified":"Updated on Nov 9, 2026"},"absolute_dates_time":{"created":"Posted on Nov 9, 2026 5:27 pm","modified":"Updated on Nov 9, 2026 12:01 pm"},"featured_img_caption":"emerging-intratumoral-cancer-therapies","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=36428"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36428\/revisions"}],"predecessor-version":[{"id":36432,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36428\/revisions\/36432"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/36430"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=36428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=36428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=36428"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=36428"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=36428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}